Bausch Health Companies Revenue and Competitors
Estimated Revenue & Valuation
- Bausch Health Companies's estimated annual revenue is currently $8.4B per year.
- Bausch Health Companies's estimated revenue per employee is $3,236,308
- Bausch Health Companies's total funding is $1.2B.
- Bausch Health Companies's current valuation is $9.7B. (January 2022)
Employee Data
- Bausch Health Companies has 2611 Employees.
- Bausch Health Companies grew their employee count by -1% last year.
Bausch Health Companies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.2M | 16 | 7% | N/A | N/A |
#2 | $30.2M | 150 | 1% | N/A | N/A |
#3 | $10.7M | 100 | 5% | $39.7M | N/A |
#4 | $104.3M | 519 | 22% | N/A | N/A |
#5 | $47.8M | 238 | N/A | N/A | N/A |
#6 | $15.5M | 77 | 5% | N/A | N/A |
#7 | $395.8M | 1969 | 7% | N/A | N/A |
#8 | $187.3M | 932 | 6% | N/A | N/A |
#9 | $361.6M | 1799 | 6% | N/A | N/A |
#10 | $27.5M | 137 | 0% | N/A | N/A |
What Is Bausch Health Companies?
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 21,000 employees are united around our mission of improving people's lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries. Five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: People, Quality Health Care Outcomes, Customer Focus, Innovation and Efficiency. More information can be found at www.bauschhealth.com. ###
keywords:N/A
$1.2B
Total Funding
2611
Number of Employees
$8.4B
Revenue (est)
-1%
Employee Growth %
$9.7B
Valuation
N/A
Accelerator
Bausch Health Companies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP North America Operations & Engineering | Reveal Email/Phone |
2 | Sr Regional Director Sales | Reveal Email/Phone |
3 | National Account Director | Reveal Email/Phone |
4 | IT Manager, Business Process | Reveal Email/Phone |
5 | Head Sales Operations | Reveal Email/Phone |
6 | Supervisory Counsel, Intellectual Property Law | Reveal Email/Phone |
7 | Business Intelligence/Data Warehouse Manager | Reveal Email/Phone |
8 | Regional Account Executive | Reveal Email/Phone |
9 | Federal Account Manager | Reveal Email/Phone |
10 | Account Manager / Orapharma | Reveal Email/Phone |
Bausch Health Companies News
(NYSE/TSX: BHC) ("Bausch Health"), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today...
Bausch Health , the specialty pharma company, is making progress in tackling its indebtedness. Bausch (ticker: BHC) said Wednesday that its...
FDA Issues Untitled Letter to Bausch Health Companies for Misleading Statements Relating to DUOBRII. Wednesday, April 20, 2022. On March 31, 2022,...
LAVAL, QC and TRENTON, N.J., Nov. 15, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 41,358,603 ...
LAVAL, QC, Nov. 4, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in upcoming investor conferences. Joseph C. Papa, chairman and chief executive officer; Sam Eldessouky, executive vice presid ...
Other Companies in Laval
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $300M | 2765 | 8% | N/A |
#2 | $1010.6M | 2876 | 5% | N/A |
#3 | $430.2M | 3073 | 7% | N/A |
#4 | $1029.3M | 3171 | 10% | N/A |
#5 | $13739.8M | 43234 | 7% | N/A |